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Gene-environment interaction between body
mass index and transforming growth factor beta 1
(TGFb1) gene in knee and hip osteoarthritis
Stella G Muthuri1, Sally Doherty2, Weiya Zhang2, Rose A Maciewicz3, Kenneth R Muir4† and Michael Doherty2*†
Abstract
Introduction: The objective was to investigate potential gene-environment interaction between body mass index
(BMI) and each of eight TGFβ1 polymorphisms in knee and hip osteoarthritis (OA).
Methods: We conducted a case-control study of Caucasian men and women aged 45 to 86 years from
Nottingham, United Kingdom (Genetics of OA and Lifestyle (GOAL) study). Cases had clinically severe symptoms
and radiographic knee or hip OA; controls had no symptoms and no radiographic knee/hip OA. We used logistic
regression to investigate the association of TGFβ1 polymorphisms and OA when stratifying by BMI. Knee and hip
OA were analyzed separately with adjustment for potential confounders. Additive and multiplicative interactions
were examined.
Results: 2,048 cases (1,042 knee OA, 1,006 hip OA) and 967 controls were studied. For hip OA, the highest risk was
in overweight (BMI ≥25 kg/m2) individuals with the variant allele of single-nucleotide polymorphism (SNP)
rs1800468 (odds ratio (OR) 2.21, 95% confidence interval (CI) 1.55, 3.15). Evaluation of gene-environment interaction
indicated significant synergetic interaction (relative excess risk due to interaction (RERI) = 0.93, synergy index (SI) =
4.33) with an attributable proportion due to interaction (AP) of 42% (AP = 0.42; 95% CI 0.16, 0.68). Multiplicative
interaction was also significant (OR for interaction (ORINT) = 2.27, P = 0.015). For knee OA, the highest risk was in
overweight individuals with homozygous genotype 11 of SNP rs2278422 (OR = 6.95, P < 0.001). In contrast, the
variant allele indicated slightly lower risks (OR = 4.72, P < 0.001), a significant antagonistic interaction (RERI = -2.66,
SI = 0.59), AP = -0.56 (95%CI -0.94, -0.17) and a significant multiplicative interaction (ORINT = 0.47, P = 0.013).
Conclusion: TGFβ1 gene polymorphisms interact with being overweight to influence the risk of large joint OA.
Introduction
Osteoarthritis (OA) is a complex disorder with genetic
and environmental risk factors both contributing to its
development and progression [1]. Obesity is one of the
strongest environmental risk factors for knee OA [2] and
is considered to be moderately associated with hip OA
[3]. Several chromosomal loci and gene variations have
also been reported to influence OA disease processes
[4,5]. Transforming growth factor beta 1 (TGFb1) gene is
one potential candidate gene for OA. TGFb1 is consid-
ered essential for cartilage integrity and is found at high
levels in normal cartilage but has reduced expression in
cartilage in OA [6]. Furthermore, increased endogenous
TGFb1 expression is reported during osteophyte forma-
tion [6,7], which reportedly stabilise joints in OA and
reduce structural progression [8].
Gene association studies have reported independent
associations with peripheral OA and spinal osteophytosis.
Within the TGFb1 gene, single nucleotide polymorphisms
(SNPs), rs2278422 and rs8179181, have been found to
have a possible role in susceptibility to knee and hip OA
in a British Caucasian population [9], and a variation on
position 29 (Leu10Pro) or SNP rs1982073 has been impli-
cated with spinal osteophytosis in Japanese postmenopau-
sal women [10]. Furthermore, increased TGFb1 expression
has been associated with body mass index (BMI)
and abdominal adipose tissue in morbid obesity [11].
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The mechanism by which body weight may exert its effect
on TGFb1 is unclear. Evidence from in vitro experiments
with human and animal culture cells as well as in vivo ani-
mal studies have shown an increased expression of TGFb1
in response to mechanical stimuli in a number of cell and
tissue types [12,13], implying that excessive biomechanical
loading of joints may stimulate the up-regulation of endo-
genous TGFb1 and thus, predispose to the development
or progression of OA.
Environmental and genetic factors may both play a role
in large joint OA but no epidemiological studies have
described possible gene environmental interactions.
Evidence from twin studies estimate that genetic factors
influence 39% to 65% of hand and knee OA in women
and about 60% of hip OA [5]. This implies that OA is not
only under the influence of genetic factors but also envir-
onmental factors and that these may modify the pene-
trance of OA susceptibility genes, even those showing
Mendelian gene inheritance. Cartilage loss and osteo-
phytes are central features in OA and weight-bearing
may impact this, therefore, we asked whether there were
any interactions in polymorphisms in genes involved in
joint tissue integrity (for example, TGFb1) and environ-
mental factors influencing weight-bearing (for example,
weight). We utilised data from the Genetics of OA and
Lifestyle (GOAL) cohort, where both body weight [14]
and polymorphisms in TGFb1 [9] have been shown to be
independent risk factors, to investigate whether being
overweight interacts with TGFb1 gene polymorphisms to
influence the risk of hip or knee OA.
Materials and methods
Participants
The GOAL study was designed as a case-control study to
characterise risk factors in large joint OA. The study was
approved by the Nottingham Research Ethics Committee
and fully informed consent was obtained. Participants
were unrelated Caucasian men and women, aged between
45 and 86 years and resident in Nottinghamshire. The
recruitment of cases and controls took place between
2002 and 2006 and details of the study are published else-
where [9,15,16]. In brief, cases were selected if they had
clinically significant symptomatic OA of the hip or knee,
sufficient to warrant hospital referral. They were recruited
if they had either undergone joint replacement, were on
the orthopaedic waiting list or had been referred with
symptomatic knee OA to the Nottingham knee OA clinic.
Controls were recruited from hospital intravenous urogra-
phy (IVU) waiting lists and frequency-matched to cases by
age (± 2 years) and gender. Controls with no evidence of
hip OA on review of their IVU radiographs were invited
to take part in the study. Only individuals that met the
study inclusion criteria were sampled [9,15,16]. The parti-
cipation rate of eligible cases and controls was 62% and
56%, respectively. This included 1,042 knee OA cases,
1,006 hip OA cases and 1,123 non OA controls.
Data collection
The GOAL study collected data using an interview-admi-
nistered questionnaire and clinical examination. The ques-
tionnaire collected information on socio-demographic
factors, employment history, occupational activity, and sig-
nificant injury, and also contained detailed questions on
other risk factors for OA. Weight (kg) and height (cm)
were measured by a trained research nurse during the
clinical examination. New knee, hand and pelvis radio-
graphs were taken at the clinical examination unless the
participant had undergone radiography not more than two
years prior to the study or had undergone total joint repla-
cement (TJR). Radiographic assessment and grading for
features of OA have been described in detail elsewhere
[9,15,16].
Genotyping
Genomic DNA was extracted from whole blood using
Gentra PureGene kit (Qiagen). TaqMan® allelic discri-
mination genotyping method was applied to detect gen-
otype polymorphisms at the TGFb1 locus as described
previously [9].
Exposure variables
Body mass index (BMI) was calculated in kg/m2 [14].
Possible confounding factors included age, sex, bone
mineral density (BMD) , nodal OA, significant joint
injury and occupational risk factors. Calcaneal bone
density (single heel determined by hand dominance) in
g/cm2 was measured using DXA (Norland Apollo
501A00Z) and the age-adjusted z-score was used for
BMD in the analysis. The presence of interphalangeal
nodes was determined during the clinical examination
and nodal OA was defined as Heberden’s and/or Bou-
chard’s nodes present in at least two x-rays of each
hand [16]. Participants self-reported previous significant
joint injury to the knee and hip joint. Also included in
the interviewer-administered questionnaire were detailed
questions about jobs held since leaving school. For each
job reported, information was sought on tasks per-
formed on an average working day that involved 12 spe-
cified occupational activities such as kneeling and
squatting as well as the weekly frequency of lifting dif-
ferent levels of weights. For this analysis, the longest
held occupation was used. We truncated occupational
exposure for patients who had undergone TJR so that
the longest held job prior to TJR was selected. This was
also truncated in all controls to the longest job held
three years earlier before the recruitment date [14].
Established occupational risk factors for knee and hip
OA including kneeling, squatting, carrying out heavy
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work whilst standing (≥1 hour), lifting 25 kg (10+ times
per week), lifting 50 kg or 100 kg (1+ times per week),
were then scored for each individual. Subsequently, each
score was summed (maximum score 6) to estimate
occupational risks.
Statistical analysis
Analyses were conducted separately on knee and hip
OA using SPSS version 18. For the present analysis, all
knee OA (n = 1,042) and hip OA (n = 1,006) patients,
and controls (n = 967) who had no symptoms and no
radiographic evidence of hip or knee OA (defined as
Kellgren-Lawrence score (KL) ≤2 at the knee and KL ≤3
at the hip joint) were included.
Participants were stratified into four strata according to
genotype (G) and BMI (E): G-/E-, G+/E-, G-/E+ and G+/E+.
Genotype 11 was defined as negative (coded as 0) and geno-
type 12 or 22 was defined as positive (coded as 1). BMI <25
kg/m2 was defined as negative (coded as 0) and BMI ≥25
kg/m2 was defined as positive (coded as 1). The ddds ratio
(OR) and 95% CI was calculated for G+/E-, G-/E+ and G+/
E+ compared with G-/E-. The study was powered to detect
an OR for interaction (ORINT) of 5 based on the multiplica-
tive model, that is, OR11 > OR01 × OR10. Unconditional
logistic regression was used to adjust for confounding. Two
models were developed: one to only adjust for age (continu-
ous variable) and gender (model 1); the other to adjust for
all putative risk factors including age, gender, BMD (contin-
uous variable), significant joint injury (yes/no), nodal OA
(yes/no) and occupational risk factors (no risk factors, and 1,
2 and 3 or more knee occupational risk factors). All statisti-
cal tests were two-sided (Wald’s c² statistic), with 5% signifi-
cance level.
To examine interaction, between gene polymorphisms
and BMI, multiplicative and additive models of interac-
tion were used. To test for multiplicative interactions,
ORs were first examined across different strata and then
an interaction term (genotype*BMI) was included in a
logistic regression model. Multivariate models were used
to adjust for covariates listed in association analyses and
a P-value below 0.05 (likelihood ratio test, LRT) was
used to indicate a significant interaction. In addition, we
assessed departure from additivity of absolute effects as
recommended by Rothman [17]. Andersson [18] has
described a detailed calculation method of additive
interaction, an SAS programme, including instructions
for how to adjust the programme for use in SPSS, and
an Excel calculator available from EpiNET [19] which
we used to estimate the three indicators of interaction
and 95% CI. The method follows the approach proposed
by Lundberg et al. [20] to calculate three measures of
additive interactions: relative excess risk due to interac-
tion (RERI), attributable proportion (AP) and synergy
index (SI), and a method suggested by Hosmer and
Lemeshow [21] to estimate 95% CI. We considered
RERI and AP to be equal to 0 and SI equal to 1 to indi-
cate absence of additive interactions [18]. Conversely,
additive interaction is considered present if RERI and
AP do not equal 0 and SI exceeds unity. Furthermore, if
RERI is greater than 0, this denotes a synergetic interac-
tion, which implies that the combined action between
two exposures in an additive model is greater than the
sum of the individual effects. However, if RERI is less
than 0, it implies an antagonistic interaction - meaning
that in the presence of two exposures in an additive
model, the action of one exposure variable diminishes
the effect of the other [17].
Results
Table 1 shows the characteristics of the OA cases and
controls. Overall, OA cases compared to controls were
significantly older, had a higher BMD, and were more
likely to be obese, to have nodal OA, to report previous
injury and to have exposure to occupational risk factors.
Stratified analysis
Table 2 shows the results of stratified analysis of TGFb1
polymorphisms, being overweight (BMI ≥25 kg/m2) and
the risk of knee OA. For example, compared with the
reference group, (that is, normal weight (BMI<25 kg/m2)
individuals carrying the wild-type genotype (11) of SNP
rs2278422, the risk for knee OA was approximately 7.0-
fold higher (OR = 6.95, 95% CI 4.22, 11.47) in overweight
individuals only, 1.4-fold (OR = 1.43, 95% CI 0.83, 2.43)
in individuals carrying the variant allele (12/22) only and
Table 1 Characteristics of the study population
Controls Knee OA
cases
Hip OA
cases
Number 967 1042 1006
Age, years (SD) 63.5 (8.5) 68.1 (7.4)* 67.6 (7.1)*
BMD, z-score (SD) 0.6 (1.2) 1.0 (1.3)* 1.0 (1.3)*
Women, % 47.2 48.6 50.5
BMI (kg/m2), % prevalence
<25 32.7 9.5 19.2%
25 to 30 43.2 36.0* 41.7*
>30 24.1 54.5* 39.2*
Nodal OA, % prevalence 10.3 28.8* 24.6*
Injury (knee or hip), %
prevalence
16.8 32.8* 22.2*
Occupational risk factors, %
prevalence
None 61.8* 48.8 57.2
1 OA risk factor 12.5 14.3 12.1
2 OA risk factors 11.7 14.1 12.4
3+ OA risk factors 14.1 22.7* 18.3*
The number per group, mean (SD) or percentage prevalence are presented.
*P <0.01, cases versus controls. OA, osteoarthritis; BMD, bone mineral density.
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4.7-fold higher (OR = 4.72. 95% CI 2.92, 7.64) when both
risk factors were present, suggesting an antagonistic
interaction between the variant allele of this polymorph-
ism and being overweight.
Similar stratified analysis for hip OA is presented in
Table 3. For example, for SNP rs1800468, the risk for hip
OA was significantly elevated in overweight individuals
only (OR = 1.71, 95% CI 1.33, 2.18) but there was no sig-
nificant association with genotype 12/22 only (P = 0.071).
However, there was a 2-fold (OR = 2.21, 95% CI 1.55,
3.15) risk for hip OA when both risk factors were pre-
sent, suggesting a synergistic interaction between the var-
iant allele of this polymorphism and being overweight.
Interaction term in the models
Table 4 shows a summary of significant results from the
analysis of interaction between TGFb1 polymorphisms
and BMI in OA (see Additional file 1 for results on all
SNPs). For knee OA, a significant antagonistic interaction
on both the multiplicative and additive scale was observed
for SNP rs2278422. Assuming a multiplicative scale, the
OR for interaction was 0.47 (95% CI 0.26, 0.86) whilst
under an additive scale, the AP was -0.61 (95% CI -0.95,
-0.27), indicating that both factors acted antagonistically
(RERI = -2.66, SI = 0.59) in relation to risk of knee OA, so
that the AP to knee OA was 61% lower than expected
from the addition of separate effects of genotype 12/22
Table 2 Risk estimates for the association of TGFb1 SNPs with knee OA by being overweight (BMI >25k g/m2)
SNP Gen OW Knee
OA
Contr Univariate Adjusted† Adjusted‡
N N OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
rs11466321 11 - 83 273 1.00 1.00 1.00
12/22 - 16 41 1.28 (0.69, 2.40) 0.436 1.19 (0.62, 2.29) 0.607 1.10 (0.54, 2.22) 0.790
11 + 770 548 4.60 (3.52, 6.02) <0.001 4.84 (3.66, 6.40) <0.001 4.08 (3.02, 5.52) <0.001
12/22 + 170 98 5.76 (4.06, 8.18) <0.001 5.75 (4.00, 8.28) <0.001 4.83 (3.28, 7.11) <0.001
rs8179181 11 - 11 15 1.00 1.00 1.00
12/22 - 87 261 0.45 (0.20, 1.03) 0.058 0.45 (0.19, 1.06) 0.068 0.53 (0.21, 1.29) 0.162
11 + 67 49 1.86 (0.79, 4.41) 0.156 1.98 (0.79, 4.93) 0.143 2.03 (0.78, 5.25) 0.147
12/22 + 862 617 1.90 (0.87, 4.17) 0.109 1.98 (0.86, 4.57) 0.110 2.01 (0.84, 4.78) 0.115
rs8105161 11 - 2 13 1.00 1.00 1.00
12/22 - 96 299 2.09 (0.46, 9.41) 0.338 2.27 (0.49, 10.58) 0.297 2.41 (0.50, 11.57) 0.271
11 + 23 18 8.31 (1.66, 41.61) 0.010 9.53 (1.83, 49.78) 0.008 9.41 (1.72, 51.60) 0.010
12/22 + 915 623 9.53 (2.14, 42.38) 0.003 10.93 (2.38, 50.21) 0.002 9.86 (2.08, 46.61) 0.004
rs2278422 11 - 28 113 1.00 1.00 1.00
12/22 - 68 197 1.39 (0.85, 2.29) 0.191 1.31 (0.78, 2.19) 0.306 1.43 (0.83, 2.48) 0.197
11 + 351 182 7.80 (4.97, 12.25) <0.001 7.57 (4.74, 12.08) <0.001 6.95 (4.22, 11.47) <0.001
12/22 + 582 462 5.07 (3.29, 7.80) <0.001 5.28 (3.38, 8.27) <0.001 4.72 (2.92, 7.64) <0.001
rs2241718 11 - 3 13 1.00 1.00 1.00
12/22 - 93 293 1.38 (0.38, 4.93) 0.625 1.37 (0.37, 5.11) 0.639 1.36 (0.35, 5.24) 0.659
11 + 29 25 5.03 (1.28, 19.67) 0.020 5.56 (1.36, 22.75) 0.017 4.86 (1.13, 20.93) 0.034
12/22 + 896 607 6.39 (1.81, 22.50) 0.004 6.73 (1.84, 24.66) 0.004 5.71 (1.50, 21.65) 0.010
rs1800468 11 - 82 258 1.00 1.00 1.00
12/22 - 15 54 0.87 (0.47, 1.63) 0.672 0.86 (0.45, 1.63) 0.637 0.92 (0.46, 1.84) 0.818
11 + 795 551 4.53 (3.45, 5.94) <0.001 4.75 (3.58, 6.31) <0.001 4.11 (3.03, 5.56) <0.001
12/22 + 134 90 4.68 (3.25, 6.75) <0.001 4.98 (3.40, 7.29) <0.001 4.16 (2.77, 6.24) <0.001
rs1800469 11 - 7 27 1.00 1.00 1.00
12/22 - 91 281 1.25 (0.53, 2.96) 0.614 1.33 (0.54, 3.25) 0.534 1.26 (0.50, 3.19) 0.626
11 + 84 59 5.43 (2.22, 13.29) <0.001 5.97 (2.36, 15.09) <0.001 5.39 (2.05, 14.12) 0.001
12/22 + 846 567 5.75 (2.49, 13.30) <0.001 6.46 (2.72, 15.39) <0.001 5.19 (2.11, 12.76) <0.001
rs1982073 11 - 38 127 1.00 1.00 1.00
12/22 - 60 180 1.11 (0.70, 1.77) 0.649 1.13 (0.70, 1.83) 0.612 1.26 (0.75, 2.10) 0.381
11 + 351 257 4.56 (3.07, 6.79) <0.001 4.95 (3.28, 7.47) <0.001 4.37 (2.82, 6.78) <0.001
12/22 + 569 374 5.07 (3.45, 7.45) <0.001 5.35 (3.58, 7.97) <0.001 4.91 (3.20, 7.53) <0.001
†Adjusted for age and gender; ‡adjusted for age, gender, nodal OA, knee injury, occupational risk factors and bone mineral density (z-score). For OW
(overweight), - indicates not overweight, + indicates overweight; TGFb1, transforming growth factor b1; OA, osteoarthritis; SNP, single nucleotide polymorphism;
Gen, genotye; OW, overweight; Contr, controls; OR, odds ratio.
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and being overweight. Additive interaction was also
observed between SNP rs11466321 and being overweight
but this effect became null after adjusting for potential
confounders. Furthermore, no statistically significant mul-
tiplicative interaction (ORINT = 1.08, P = 0.851) was
found for this SNP (Table 4).
For hip OA, an additive interaction was observed
between SNP rs1800468 and being overweight. Both fac-
tors acted synergistically (RERI = 0.93, SI = 4.33) to
increase the risk of hip OA, so that among overweight
persons carrying the variant allele, 42% (AP = 0.42; 95%
CI 0.16, 0.68) of hip OA risk was attributable to the
action of both exposures as compared with the contri-
bution of each of the two risk factors added to each
other. A significant multiplicative interaction (ORINT =
2.27, P = 0.015) for this SNP was also found (Table 4).
Discussion
This is the first study to examine possible interactions
between increased BMI and TGFb1 gene polymorphisms
for knee and hip OA. We found significant additive and
multiplicative interaction between being overweight and
the variant allele of TGFb1 SNP rs2278422 in knee OA
but in hip OA these interactions were indicated by
TGFb1 SNP rs1800468.
Obesity is a known risk for OA and it has been postu-
lated that in addition to the impact on joint mechanics
[22,23] there may be a link between dysfunctional meta-
bolism and joint damage via adipose-secreted cytokines
termed adipokines, which are known regulators of meta-
bolic homeostasis [24,25]. In vitro experiments with
human and animal culture cells as well as in vivo animal
studies have shown an increased expression of TGFb1 in
Table 3 Risk estimates for the association of TGFb1 SNPs with hip OA by being overweight (BMI >25 kg/m2)
SNP Genotype Overweight Hip OA Controls Univariate Adjusted† Adjusted‡
N N OR (95% CI) P-value ORs (95% CI) P-value ORs (95% CI) P-value
rs11466321 11 - 162 273 1.00 1.00 1.00
12/22 - 30 41 1.23 (0.74, 2.05) 0.420 1.22 (0.72, 2.06) 0.466 1.18 (0.68, 2.05) 0.552
11 + 683 548 2.10 (1.68, 2.63) <0.001 2.25 (1.78, 2.84) <0.001 1.97 (1.54, 2.53) <0.001
12/22 + 125 98 2.17 (1.56, 3.02) <0.001 2.22 (1.58, 3.12) <0.001 1.92 (1.34, 2.74) <0.001
rs8179181 11 - 17 15 1.00 1.00 1.00
12/22 - 197 261 0.67 (0.32, 1.37) 0.268 0.57 (0.27, 1.21) 0.143 0.72 (0.33, 1.56) 0.404
11 + 43 49 0.77 (0.35, 1.73) 0.534 0.75 (0.32, 1.75) 0.505 0.79 (0.33, 1.90) 0.602
12/22 + 728 617 1.04 (0.52, 2.11) 0.907 0.94 (0.45, 1.97) 0.871 1.03 (0.48, 2.21) 0.944
rs8105161 11 - 9 13 1.00 1.00 1.00
12/22 - 182 299 0.88 (0.37, 2.10) 0.772 0.95 (0.39, 2.31) 0.906 0.94 (0.38, 2.33) 0.890
11 + 19 18 1.52 (0.52, 4.43) 0.438 1.78 (0.59, 5.34) 0.304 1.75 (0.57, 5.41) 0.329
12/22 + 790 623 1.83 (0.78, 4.32) 0.165 2.09 (0.87, 5.03) 0.098 1.82 (0.74, 4.45) 0.189
rs2278422 11 - 66 113 1.00 1.00 1.00
12/22 - 126 197 1.10 (0.75, 1.60) 0.637 1.08 (0.73, 1.60) 0.703 1.07 (0.71, 1.60) 0.751
11 + 260 182 2.46 (1.72, 3.52) <0.001 2.55 (1.76, 3.70) <0.001 2.26 (1.53, 3.33) <0.001
12/22 + 542 462 2.01 (1.45, 2.79) <0.001 2.14 (1.52, 3.02) <0.001 1.85 (1.29, 2.65) 0.001
rs2241718 11 - 9 13 1.00 1.00 1.00
12/22 - 182 293 0.90 (0.38, 2.14) 0.807 0.95 (0.39, 2.31) 0.905 0.95 (0.38, 2.35) 0.908
11 + 23 25 1.33 (0.48, 3.69) 0.585 1.60 (0.56, 4.59) 0.377 1.59 (0.54, 4.67) 0.395
12/22 + 766 607 1.83 (0.78, 4.30) 0.168 2.04 (0.85, 4.90) 0.112 1.78 (0.73, 4.36) 0.205
rs1800468 11 - 174 258 1.00 1.00 1.00
12/22 - 17 54 0.47 (0.26, 0.83) 0.010 0.52 (0.28, 0.93) 0.029 0.57 (0.31, 1.05) 0.071
11 + 661 551 1.78 (1.43, 2.23) <0.001 1.92 (1.52, 2.42) <0.001 1.71 (1.33, 2.18) <0.001
12/22 + 140 90 2.31 (1.66, 3.20) <0.001 2.47 (1.75, 3.47) <0.001 2.21 (1.55, 3.15) <0.001
rs1800469 11 - 13 27 1.00 1.00 1.00
12/22 - 178 281 1.32 (0.66, 2.62) 0.434 1.39 (0.68, 2.84) 0.362 1.37 (0.66, 2.85) 0.396
11 + 65 59 2.29 (1.08, 4.84) 0.030 2.46 (1.13, 5.35) 0.024 2.09 (0.94, 4.65) 0.072
12/22 + 727 567 2.67 (1.36, 5.22) 0.004 3.00 (1.50, 6.02) 0.002 2.61 (1.28, 5.35) 0.009
rs1982073 11 - 74 127 1.00 1.00 1.00
12/22 - 112 180 1.07 (0.74, 1.55) 0.729 1.11 (0.76, 1.63) 0.594 1.22 (0.82, 1.83) 0.323
11 + 294 257 1.96 (1.41, 2.74) <0.001 2.22 (1.57, 3.14) <0.001 2.06 (1.44, 2.95) <0.001
12/22 + 498 374 2.29 (1.67, 3.14) <0.001 2.45 (1.76, 3.40) <0.001 2.27 (1.61, 3.20) <0.001
For Overweight, -indicates not overweight, + indicates overweight; †adjusted for age and gender; ‡adjusted for age, gender, nodal OA, hip injury, occupational
risk factors and bone mineral density (Z score); TGFb1, transforming growth factor b1; SNP, single nucleotide polymorphism; OA, osteoarthritis; OR, odds ratio.
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response to mechanical stimuli in a number of cell and
tissue types [6,7,12,13]. Furthermore, experimental mod-
els have found excess endogenous TGFb in association
with both chondrocyte synthesis and osteophyte forma-
tion [6,7]. Leptin may also play a key role in the develop-
ment of OA mainly through mechanisms that modulate
TGFb function in maintaining cartilage and bone integ-
rity [24,25]. There is evidence of increased leptin expres-
sions in synovial fluid and in cartilage and osteophytes of
patients with OA [24]. Therefore, it is plausible that
excessive biomechanical loading of joints or stimulation
by adipokines such as leptin may stimulate the up-regula-
tion of endogenous TGFb1, leading to formation of new
fibrocartilage that then undergoes endochondral ossifica-
tion to become osteophytes. This hypothesis may partly
explain the antagonistic interaction that was observed in
this study between being overweight and the variant
allele of the TGFb1 polymorphism rs2278422 in knee
OA (Table 4). A previously reported association using
the GOAL population found the heterozygous genotype
of the TGFb1 polymorphism rs2278422 to be associated
with reduced risk of knee OA [9].
On the other hand, we found increased BMI to inter-
act with the variant allele of SNP rs1800468 to increase
the risk of hip OA (Table 4). This finding suggests that
a greater body weight increased the risk of hip OA in
this population, but overweight individuals with the var-
iant allele of TGFb1 SNP rs1800468 appeared to have
an even greater risk (Table 3). Our previous association
analysis did not find a statistically significant association
between SNP rs1800468 and hip OA, further demon-
strating that on its own, it did not influence risk for hip
OA in this population [9]. These different findings at
the knee and hip further support consideration of OA at
these two sites to be discrete subsets in terms of risk
factor profile.
The functional relevance of these TGFb1 variants
remains unknown. The location of SNP rs1800468 in the
promoter genomic region (5’UTR) suggests that it may
play a role in gene regulation and signal sequence. SNP
rs2278422 resides in intron 8, a region of unknown biolo-
gical importance. Nevertheless, we cannot exclude the
possibility that the observed interactions may be due to
linkage disequilibrium (LD). For example, SNP rs1800468
has been found to be in LD with SNP rs1800469 [26] and
SNP rs1800469 is also reported to be in strong LD with
rs1982073 [27]. Therefore, it is conceivable that these
interactions may result from this SNP being tightly linked
to another susceptibility genetic variant of biological
importance.
Some of the strengths of this study include: a well-char-
acterised cohort; a sufficient sample size to detect modest
interactions in a case-control design; and radiographic
data on the control population. In addition, confounding
resulting from population stratification was minimised, as
all participants were Caucasian and were recruited from a
homogenous geographical area.
However, this study also has several caveats. First, we
recruited hospital cases and controls which may have led
to selection bias. Cases were patients with clinically severe
symptoms of OA sufficient to warrant hospital referral, so
these findings may not be extrapolated to the full spec-
trum of OA patients. Second, controls were recruited
from IVU lists, and hence are more likely to suffer from
kidney disease, including malignancy. Although none of
these conditions have any known positive or negative asso-
ciation with OA, controls with these diagnoses may be
positively or negatively associated with the TGFb1 gene
Table 4 Significant results from gene-environment interactions of TGFb1 SNPs and BMI in OA
TGFb1 SNP OA phenotyp Interaction Univariate Adjusted‡ OR
ORINT (95% CI) P-Value (LRT) ORINT (95% CI) P-Value (LRT)
rs11466321 Knee OA Multiplicative 0.96 (0.49, 1.91) 0.911 1.08 (0.50, 2.31) 0.851
RERI 4.25 (2.46, 6.05) 0.67 (-0.92, 2.26)
AP 0.75 (0.59, 0.90) 0.14 (-0.16, 0.44)
Synergy Index 10.46 (1.42, 77.30) 1.21 (0.77, 1.89)
rs2278422§ Knee OA Multiplicative 0.47 (0.27, 0.81) 0.005 0.47 (0.26, 0.86) 0.013
RERI -3.09 (-5.37, -0.81) -2.66 (-4.96, -0.36)
AP -0.61 (-0.95, -0.27) -0.56 (-0.94, -0.17)
Synergy Index 0.57 (0.45, 0.72) 0.59 (0.44, 0.78)
rs1800468¶ Hip OA Multiplicative 2.78 (1.46, 5.30) 0.001 2.27 (1.15, 4.48) 0.015
RERI 1.06 (0.38, 1.75) 0.93 (0.19, 1.67)
AP 0.46 (0.24, 0.68) 0.42 (0.16, 0.68)
Synergy Index 5.32 (0.72, 39.11) 4.33 (0.59, 31.96)
‡Adjusted for age, gender, nodal OA, joint injury, occupational risk factors and bone mineral density (z-score). §Statistically significant with RERI <0, AP <0, and
synergy index (SI) <1 indicating an antagonistic interaction. ¶Statistically significant with RERI >0, AP >0, and SI >1, indicating a synergetic interaction. TGFb1,
transforming growth factor b1; SNP, single nucleotide polymorphism; BMI, body mass index; OA, osteoarthritis; OR, odds ratio; ORINT, odds ratio for interaction;
LRT, likelihood ratio test; RERI, relative excess risk due to interaction; AP, attributable proportion.
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and result in exaggerated risks. Nevertheless, this was
unlikely to have affected our findings since the TGFb1
polymorphisms we examined did not deviate from Hardy-
Weinberg Equilibrium (HWE) in the control population.
Third, the study measured cross-sectional weight and
height at the end-stage of the disease. Therefore, it is not
possible to determine whether being overweight preceded
OA or was the consequence of it. Despite this limitation,
BMI provided a more reliable proxy indicator for mechan-
ical stresses compared to physical activity and occupa-
tional risk factors, which were more prone to recall bias.
Fourth, we carried out a number of multiple statistical
tests but no adjustments were made, which may have
resulted in false positive significant interactions. A com-
mon approach used in many studies to attempt to reduce
the number of polymorphisms tested is to restrict gene-
environment interaction analysis only to gene variants that
show significant association with the outcome. However,
this approach gives little consideration to a large environ-
mental risk component such as BMI in OA. Instead, we
have described and provided the tests of significance used
as recommended by Pernerger [28] as a way of dealing
with multiple testing. Finally, our results were not repli-
cated in a separate independent dataset, therefore, future
studies are needed to validate these findings in different
populations and study settings.
Conclusions
In conclusion, we have identified for the first time
potential interaction between TGFb1 and being over-
weight in large joint OA. The results were supported by
both multiplicative and additive models and appeared to
differ between knee and hip OA. The results require
replication in other populations and if confirmed,
further molecular studies are warranted to better under-
stand the underlying mechanisms responsible for such
interactions in OA.
Additional material
Additional file 1: Additive and multiplicative gene-environment
interactions in knee and hip osteoarthritis. This file contains two
tables with results on additive and multiplicative gene-environment
interactions among transforming growth factor (TGF)b1 single nucleotide
polymorphisms (SNPs), body mass index (BMI) and osteoarthritis (OA).
Table S1: Gene-environment interactions among TGFb1 SNPs, BMI and
knee OA. Table S2: Gene-environment interactions among TGFb1 SNPs,
BMI and hip OA.
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